HLA Evolutionary Divergence (HED) Informs the Effect of HLA-B Mismatch on Outcomes After Haploidentical Transplantation

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2024 Jul 31

PMID 39085372

Authors

Melhem Solh

Michael T Aubrey

Xu Zhang

Asad Bashey

Brian M Freed

Christina L Roark

Lizamarie Bachier-Rdriguez

Lawrence E Morris

H Kent Holland

Scott R Solomon

Affiliations

Soon will be listed here.

Abstract

Graft versus tumor relies on tumor-associated antigens (TAAs) that are presented to donor T cells via human leukocyte antigens (HLAs). The HLA evolutionary divergence (HED) between alleles of a single individual can dictate the ability to present TAAs. The impact of HED in haploidentical donor transplantation (HIDT) has not been studied. We studied the effect of HED on transplant outcomes following HIDT. We analyzed 322 consecutive recipient/donor pairs with a median follow-up of 57.2 months. Pairwise divergence of HLA class I and II showed that HLA-B, -DRB1, and -DQB1 contributing most to mean HED. The mean HED was class I 6.85 (HLA-A 7.08, -B 8.24, and -C 5.07), class II 8.58 (HLA-DRB1 10.97, -DQB1 10.06 and -DPB1 4.06). A high HED in class I mismatched recipient/donor haplotype (RD MM) was significant for worse DFS (HR 1.11, p = 0.020), and relapse (HR 1.11, p = 0.02). Also, a high HED in RD MM HLA-B haplotype had worse OS (HR 1.07, p = 0.02), DFS (HR 1.09, p = 0.002), higher relapse (HR 1.10, p = 0.003), and similar NRM to low HED. The multivariate analysis showed that high HED in RD MM HLA-B (≥7.8 vs <7.8) had worse DFS (HR 1.53, p = 0.01), higher relapse (HR 1.61, p = 0.024), and similar NRM and OS.

References

Sweeney C, Vyas P . The Graft-Versus-Leukemia Effect in AML. Front Oncol. 2019; 9:1217. PMC: 6877747. DOI: 10.3389/fonc.2019.01217. View

Rezvani K, Yong A, Savani B, Mielke S, Keyvanfar K, Gostick E . Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood. 2007; 110(6):1924-32. PMC: 1976363. DOI: 10.1182/blood-2007-03-076844. View

Pierini F, Lenz T . Divergent Allele Advantage at Human MHC Genes: Signatures of Past and Ongoing Selection. Mol Biol Evol. 2018; 35(9):2145-2158. PMC: 6106954. DOI: 10.1093/molbev/msy116. View

Paul S, Weiskopf D, Angelo M, Sidney J, Peters B, Sette A . HLA class I alleles are associated with peptide-binding repertoires of different size, affinity, and immunogenicity. J Immunol. 2013; 191(12):5831-9. PMC: 3872965. DOI: 10.4049/jimmunol.1302101. View

Chowell D, Krishna C, Pierini F, Makarov V, Rizvi N, Kuo F . Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nat Med. 2019; 25(11):1715-1720. PMC: 7938381. DOI: 10.1038/s41591-019-0639-4. View

Grantham R . Amino acid difference formula to help explain protein evolution. Science. 1974; 185(4154):862-4. DOI: 10.1126/science.185.4154.862. View

Parham P, Ohta T . Population biology of antigen presentation by MHC class I molecules. Science. 1996; 272(5258):67-74. DOI: 10.1126/science.272.5258.67. View

Hernandez P, Duffy B, Hock K, Farnsworth C, Schindler E, Liu C . HLA-B evolutionary divergence is associated with outcomes after SARS-CoV-2 infection. Hum Immunol. 2022; 83(12):803-807. PMC: 9464580. DOI: 10.1016/j.humimm.2022.09.004. View

Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M . Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009; 15(3):367-9. PMC: 3110087. DOI: 10.1016/j.bbmt.2008.12.497. View

10.

Luznik L, ODonnell P, Symons H, Chen A, Leffell M, Zahurak M . HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008; 14(6):641-50. PMC: 2633246. DOI: 10.1016/j.bbmt.2008.03.005. View

11.

Solomon S, Sizemore C, Sanacore M, Zhang X, Brown S, Holland H . Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free.... Biol Blood Marrow Transplant. 2012; 18(12):1859-66. DOI: 10.1016/j.bbmt.2012.06.019. View

12.

Robinson J, Guethlein L, Cereb N, Yang S, Norman P, Marsh S . Distinguishing functional polymorphism from random variation in the sequences of >10,000 HLA-A, -B and -C alleles. PLoS Genet. 2017; 13(6):e1006862. PMC: 5507469. DOI: 10.1371/journal.pgen.1006862. View

13.

Daull A, Dubois V, Labussiere-Wallet H, Venet F, Barraco F, Ducastelle-Lepretre S . Class I/Class II HLA Evolutionary Divergence Ratio Is an Independent Marker Associated With Disease-Free and Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Front Immunol. 2022; 13:841470. PMC: 8931406. DOI: 10.3389/fimmu.2022.841470. View

14.

Joris M, van Rood J, Roelen D, Oudshoorn M, Claas F . A proposed algorithm predictive for cytotoxic T cell alloreactivity. J Immunol. 2012; 188(4):1868-73. DOI: 10.4049/jimmunol.1102086. View

15.

Joris M, Lankester A, von dem Borne P, Kuball J, Bierings M, Cornelissen J . The impact of frequent HLA haplotypes in high linkage disequilibrium on donor search and clinical outcome after unrelated haematopoietic SCT. Bone Marrow Transplant. 2012; 48(4):483-90. DOI: 10.1038/bmt.2012.189. View

16.

Heemskerk M, Roelen D, Dankers M, van Rood J, Claas F, Doxiadis I . Allogeneic MHC class I molecules with numerous sequence differences do not elicit a CTL response. Hum Immunol. 2005; 66(9):969-76. DOI: 10.1016/j.humimm.2005.06.007. View

17.

Mattson D, Shimojo N, Cowan E, Baskin J, Turner R, Shvetsky B . Differential effects of amino acid substitutions in the beta-sheet floor and alpha-2 helix of HLA-A2 on recognition by alloreactive viral peptide-specific cytotoxic T lymphocytes. J Immunol. 1989; 143(4):1101-7. View

18.

Kosmoliaptsis V, Joris M, Mallon D, Lankester A, von dem Borne P, Kuball J . Physiochemical disparity of mismatched HLA class I alloantigens and risk of acute GVHD following HSCT. Bone Marrow Transplant. 2015; 50(4):540-4. DOI: 10.1038/bmt.2014.305. View

19.

Schellens I, Hoof I, Meiring H, Spijkers S, Poelen M, van Gaans-van den Brink J . Comprehensive Analysis of the Naturally Processed Peptide Repertoire: Differences between HLA-A and B in the Immunopeptidome. PLoS One. 2015; 10(9):e0136417. PMC: 4574158. DOI: 10.1371/journal.pone.0136417. View

20.

Blais M, Dong T, Rowland-Jones S . HLA-C as a mediator of natural killer and T-cell activation: spectator or key player?. Immunology. 2011; 133(1):1-7. PMC: 3088962. DOI: 10.1111/j.1365-2567.2011.03422.x. View